Sign in Subscribe
United States. Securities and Exchange Commission

Mallinckrodt plc Faces Financial Uncertainty Amid Investor Demands and Opioid Settlement Obligations

Strategic Insights

— 2 min read

Mallinckrodt plc, a pharmaceutical company based in Ireland, has been facing significant financial pressure as it navigates its obligations under the opioid settlement. The company, which has been struggling with financial issues, has received unsolicited letters from investors holding substantial positions in the company's capital structure. These investors, including holders of the company's 2025 First Lien Notes and 2025 Second Lien Notes, have requested that the company's board of directors and management team evaluate its financial wherewithal and consider alternative options to meet its financial responsibilities.

The investors have proposed various transactions, including the possibility of a sale of assets under Chapter 11 of the U.S. Bankruptcy Code. The company has also commenced preliminary discussions with the Opioid Master Disbursement Trust II (the "Trust") about alternatives to the existing payment structure for the opioid settlement. However, the Trust has demanded payment be made timely, and the company's board is actively evaluating this situation, considering options, and engaging in discussions with various parties.

Key Takeaways:

  • Mallinckrodt plc has received unsolicited letters from investors holding substantial positions in the company's capital structure, including holders of the 2025 First Lien Notes and 2025 Second Lien Notes.
  • The investors have requested that the company's board of directors and management team evaluate its financial wherewithal and consider alternative options to meet its financial responsibilities.
  • The company has commenced preliminary discussions with the Opioid Master Disbursement Trust II (the "Trust") about alternatives to the existing payment structure for the opioid settlement.
  • The Trust has demanded payment be made timely, and the company's board is actively evaluating this situation, considering options, and engaging in discussions with various parties.
  • The company may potentially initiate proceedings under Chapter 11 of the U.S. Bankruptcy Code or foreign bankruptcy or insolvency laws.
  • The company's substantial indebtedness and ability to generate sufficient cash to service indebtedness are significant risks and uncertainties.
  • The company's ability to achieve expected benefits from its prior restructuring activities and its ability to incur further indebtedness are also important factors to consider.

Statistics:

  • $200 million: the amount of the payment required by the company's opioid settlement to be made to the Opioid Master Disbursement Trust II on June 16, 2023.
  • 2025: the year by which the company's 2025 First Lien Notes and 2025 Second Lien Notes are due.
  • 11.5% and 10.0%: the interest rates on the company's 2028 First Lien Notes and 2025 Second Lien Notes, respectively.
  • June 16, 2022: the date of the Credit Agreement under which the company's Term Loan Holders issued the company's 2027 Term Loan.
  • May 17, 2023: the date on which the company received the first of the unsolicited letters from investors.

Sources:

  • United States Securities and Exchange Commission
  • Mallinckrodt plc
  • Opioid Master Disbursement Trust II

Read more